A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Idiopathic Anemia of Aging (IAA) Receiving Epoetin Alfa (PROCRIT�)

Sponsors

Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Collaborator: Ortho Biotech Products, L.P.

Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Brief Summary

The purpose of this study is to assess changes in physical function in elderly patients (>= 65 years of age) with chronic anemia (Hb <= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo.

Detailed Description

.Some elderly patients have anemia (reduction in hemoglobin level, or low red cell count) without obvious cause. Anemia occurs commonly with aging and is a frequent medical condition in individuals over the age of 65. Physical performance and function is worse in individuals who are anemic. This is a randomized, double-blind, placebo-controlled, multi-center study to assess physical function (to include falls) and fatigue in approximately 80 elderly patients with chronic anemia (anemia present for at least 3 months) and who are receiving weekly Epoetin alfa. The study will also evaluate hemoglobin levels (oxygen carrying protein in red blood cells), safety, fatigue and cognitive function. The study hypothesis is to demonstrate the study drug will be more effective in treatment of chronic anemia than placebo, resulting in the improvement of physical function and subsequent disabilities, with minimal adverse events and the study drug is generally well-tolerated. The patients will receive weekly injections of Epoetin alfa (PROCRIT®) or placebo at a starting dose of 10,000 units administered subcutaneously (under the skin).

Overall Status Terminated
Start Date June 2004
Completion Date September 2005
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
To assess the change in physical function from baseline to end of study as measured by the Short Physical Performance Battery (SPPB) summary score.
Secondary Outcome
Measure Time Frame
To assess: Efficacy of Procrit by achieving a target Hb of 12.5-12.9 g/dL; Change in FACT-An score; Change in Six-Minute Walk Test, Safety (Adverse Event incidence, Lab Tests, and Vitals); Cognitive function; Number and type of injuries from falls
Enrollment 9
Condition
Intervention

Intervention Type: Drug

Intervention Name: epoetin alfa

Eligibility

Criteria:

Inclusion Criteria:

- Patients with a history of chronic anemia defined as a documented Hb value of <= 11.0 g/dL

- No active cancer

- At least 65 years of age with life expectancy of > 6 months

- Community dwelling patients

- Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening and baseline

- Patients with a Mini Mental State Examination (MMSE) score >= 24

Exclusion Criteria:

- Positive stool guaiac test

- Diagnosis of multiple myeloma and/or MGUS

- History of venous thromboembolytic disease

- Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin recently

- Uncontrolled or severe cardiovascular disease

Gender: All

Minimum Age: 65 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial Study Director Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Verification Date

April 2010

Keywords
Condition Browse
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Double

Source: ClinicalTrials.gov